Leerink Partnrs Has Positive Outlook of WVE FY2027 Earnings

Key Points

• Leerink Partners has raised its FY2027 earnings per share estimate for WAVE Life Sciences Ltd. from ($0.33) to ($0.28), indicating a more optimistic outlook for the company's financial performance.
• WAVE Life Sciences recently reported a quarterly EPS of ($0.31), missing estimates by ($0.02), alongside revenue of $8.70 million which was below expectations of $11.52 million.
• Despite some fluctuations in price targets by various brokerages, the consensus maintains a "Moderate Buy" rating for the company's stock, with an average target price of $20.07.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at Leerink Partnrs lifted their FY2027 EPS estimates for WAVE Life Sciences in a research note issued on Wednesday, September 3rd. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.28) per share for the year, up from their previous forecast of ($0.33). The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $11.52 million.

Several other brokerages also recently commented on WVE. Citigroup started coverage on shares of WAVE Life Sciences in a research report on Wednesday, July 16th. They set a "buy" rating and a $16.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of WAVE Life Sciences in a report on Wednesday, September 3rd. Canaccord Genuity Group started coverage on shares of WAVE Life Sciences in a report on Monday, August 4th. They set a "buy" rating and a $19.00 price target for the company. Oppenheimer started coverage on shares of WAVE Life Sciences in a report on Monday, July 28th. They set an "outperform" rating and a $24.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on shares of WAVE Life Sciences from $21.00 to $18.00 and set an "overweight" rating for the company in a report on Thursday. Fourteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $20.07.

WAVE Life Sciences Price Performance

Shares of WVE opened at $8.29 on Monday. WAVE Life Sciences has a one year low of $5.04 and a one year high of $16.74. The company has a market cap of $1.32 billion, a P/E ratio of -9.21 and a beta of -1.16. The firm has a 50 day simple moving average of $8.43 and a two-hundred day simple moving average of $7.87.

Insider Buying and Selling at WAVE Life Sciences

In related news, Director Gregory L. Verdine sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $10.00, for a total value of $100,000.00. Following the sale, the director owned 285,217 shares of the company's stock, valued at $2,852,170. The trade was a 3.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ken Takanashi sold 4,872 shares of the business's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $8.75, for a total transaction of $42,630.00. Following the completion of the sale, the director directly owned 5,716,303 shares in the company, valued at approximately $50,017,651.25. This represents a 0.09% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 271,893 shares of company stock worth $2,631,568. Company insiders own 23.98% of the company's stock.

Institutional Trading of WAVE Life Sciences

Institutional investors have recently bought and sold shares of the company. Virtus Investment Advisers LLC boosted its holdings in WAVE Life Sciences by 10.2% in the 2nd quarter. Virtus Investment Advisers LLC now owns 13,060 shares of the company's stock valued at $85,000 after purchasing an additional 1,210 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in WAVE Life Sciences by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 18,673 shares of the company's stock valued at $151,000 after purchasing an additional 1,564 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in WAVE Life Sciences by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company's stock valued at $74,000 after purchasing an additional 1,802 shares during the period. Velan Capital Investment Management LP boosted its holdings in WAVE Life Sciences by 15.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 15,000 shares of the company's stock valued at $98,000 after purchasing an additional 2,000 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of WAVE Life Sciences by 8.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company's stock worth $188,000 after acquiring an additional 2,206 shares during the last quarter. Institutional investors own 89.73% of the company's stock.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.